What is Sweet syndrome and is it associated with meningioma?

What is Sweet Syndrome?

Sweet syndrome (acute febrile neutrophilic dermatosis) is an inflammatory condition characterized by fever, neutrophilia, and painful erythematous skin lesions (papules, nodules, or plaques) with a distinctive histologic finding of dense neutrophilic infiltration in the upper dermis without vasculitis 1, 2.

Clinical Presentation

The syndrome typically presents with:

• Fever and elevated neutrophil count
• Tender, painful red skin lesions - most commonly on the face, neck, and upper extremities, often distributed asymmetrically 1
• Systemic manifestations - can involve eyes, muscles, joints, kidneys, lungs, and liver 3
• Neurologic involvement (Neuro-Sweet syndrome) - rare but important, manifesting as aseptic meningoencephalitis 4

Classification and Associations

Sweet syndrome is categorized into three types 5, 6:

1. Classical/Idiopathic Sweet syndrome (CSS) - 53-77% of cases
2. Malignancy-associated Sweet syndrome (MASS) - 20-35% of cases
3. Drug-induced Sweet syndrome (DISS) - 3-12% of cases

Critical Association with Malignancy

In malignancy-associated cases, hematologic neoplasms predominate, with acute myelogenous leukemia being the most common underlying cancer 3. Other associated malignancies include lymphomas, chronic leukemias, myelomas, myelodysplastic syndromes, and various solid tumors 5, 3.

The onset of Sweet syndrome either preceded or coincided with the discovery of previously undiagnosed cancer in over 60% of malignancy-associated cases 3. This makes Sweet syndrome a potential paraneoplastic marker requiring thorough malignancy screening.

Key Clinical Differences in Malignancy-Associated Cases

Patients with malignancy-associated Sweet syndrome present differently than those with idiopathic disease 3:

• More severe cutaneous lesions
• Cytopenias and/or immature cells in peripheral blood
• Lower mean hemoglobin levels (statistically significant in both males and females, p < 0.0443 and p < 0.0035 respectively) 5

Is Sweet Syndrome Associated with Meningioma?

No, Sweet syndrome is NOT associated with meningioma. The provided evidence extensively discusses meningioma molecular markers and targeted therapies 7, 8, but there is no documented association between Sweet syndrome and meningioma in the medical literature reviewed.

The confusion may arise from the term "Neuro-Sweet syndrome," which refers to neurologic involvement of Sweet syndrome presenting as aseptic meningoencephalitis 4 - this is inflammation of the brain and meninges, NOT a meningioma (which is a tumor arising from the meninges).

Important Distinction:

• Neuro-Sweet syndrome = Sweet syndrome with CNS inflammation (meningoencephalitis)
• Meningioma = A tumor of the meninges, unrelated to Sweet syndrome

Treatment Approach

Systemic corticosteroids are the gold standard first-line treatment for Sweet syndrome, resulting in dramatic improvement regardless of underlying malignancy response 2, 3. Treatment typically includes:

• First-line: Systemic corticosteroids (used in 70% of cases) 5
• Alternative first-line options (when corticosteroids contraindicated or systemic infection present):
  • Potassium iodide
  • Colchicine 2
• Second-line options: Indomethacin, clofazimine, dapsone, cyclosporine 2

Critical Clinical Pitfall

The most important pitfall is failing to categorize Sweet syndrome cases and screen for underlying malignancy 6. In one study, 53% of cases were not categorized by clinicians, and three of these patients were subsequently diagnosed with malignancy up to 19 months later 6.

Any patient presenting with Sweet syndrome requires:

• Complete blood count with differential
• Evaluation for anemia (particularly important as lower hemoglobin predicts malignancy-associated disease) 5
• Age-appropriate cancer screening
• Bone marrow examination if cytopenias or abnormal cells present
• Follow-up monitoring, as Sweet syndrome may herald clonal evolution in myeloproliferative disorders 9